Compare THH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THH | BIVI |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.4M |
| IPO Year | 2025 | 2013 |
| Metric | THH | BIVI |
|---|---|---|
| Price | $1.32 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.26 |
| AVG Volume (30 Days) | 15.0K | ★ 839.8K |
| Earning Date | 11-21-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.82 |
| 52 Week High | $56.26 | $3.79 |
| Indicator | THH | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.22 | 47.50 |
| Support Level | $0.27 | $1.15 |
| Resistance Level | $1.50 | $1.42 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 22.92 | 14.48 |
Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.